Application of circular RNA in preparation of cerebral stroke diagnosis product

By detecting the expression of circular RNA-circ-Magi1, the problems of inaccurate and expensive early diagnosis of existing strokes are solved, and a fast, accurate and inexpensive diagnosis method is provided, which improves the early diagnosis of stroke. Accuracy and provides new ideas for prevention and treatment.

WO2023227121A9PCT designated stage expired Publication Date: 2024-12-05YUANSHENG BIOTECH (TSING DAO) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/096620
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-05-26
Filing Date
2023-05-26
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The existing stroke diagnosis methods have problems such as inaccurate early diagnosis, high cost and inapplicable to some patients. In particular, CT examinations are not effective in judging early ischemic stroke, high MRI costs and cardiac beats Patients with instruments or magnetic metals in the body are not suitable for use, and there is a lack of fast, accurate and inexpensive diagnosis methods.

Method used

By detecting the expression of circular RNA-circ-Magi1, a kit and detection system are provided for diagnostic, auxiliary diagnostic or prognostic evaluation, and the content of circ-Magi1 is analyzed in blood or tissue using detection primers and fluorescence quantitative PCR technology. Establish a scoring model to assist in the diagnosis of stroke.

Benefits of technology

Improve the accuracy of early diagnosis of stroke, provides a fast, accurate and inexpensive method, which can produce results as soon as the patient is admitted to the hospital, avoid missing the golden treatment time, and provide new for the prevention and treatment of stroke ideas.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023096620_05122024_PF_FP_ABST
    Figure CN2023096620_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is an application of a circular RNA in the preparation of a cerebral stroke diagnosis product, belonging to the field of circular RNA medical treatments. Provided is a kit, comprising a reagent and / or test paper and / or gene chip for detecting a circular RNA-circ-Magi1. The nucleotide sequence of the circular RNA-circ-Magi1 is as shown in SEQ ID NO: 1 or SEQ ID NO: 4. Further provided is the application of a detection system for the diagnosis, assisted diagnosis or prognosis evaluation of cerebral stroke, and a detection reagent of the circular RNA-circ-Magi1 in the preparation of a kit, test paper, chip or high-throughput sequencing platform for the diagnosis, assisted diagnosis or prognosis evaluation of cerebral stroke.
Need to check novelty before this filing date? Find Prior Art

Description

Application of a circular RNA in the preparation of stroke diagnostic products

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese patent application No. 2022105821606, filed on May 26, 2022, entitled “Application of a circular RNA in the preparation of stroke diagnostic products,” the entire text of which is hereby incorporated by reference. Technical Field

[0003] The present application relates to the medical field of circular RNA, specifically to a circular RNA-circ-Magi1, a kit for diagnosing, assisting in the diagnosis or prognostic evaluation of stroke, a detection system for diagnosing, assisting in the diagnosis or prognostic evaluation of stroke, and the use of a detection reagent for circular RNA-circ-Magi1 in the preparation of a kit, test paper, chip or high-throughput sequencing platform for diagnosing, assisting in the diagnosis or prognostic evaluation of stroke. Background Art

[0004] A cerebral stroke (also known as a stroke) is an acute cerebrovascular disease caused by rupture or blockage of a cerebral blood vessel, resulting in blood flow to the brain and causing brain damage. It includes both ischemic and hemorrhagic strokes. Stroke is characterized by high morbidity, mortality, disability, and recurrence rates. Stroke has become the leading cause of death in my country and the leading cause of disability among adults in the country.

[0005] Currently, conventional stroke diagnosis relies mainly on clinical symptoms supplemented by imaging techniques and blood tests. Blood molecular markers are increasingly becoming important indicators to aid diagnosis.

[0006] With the deepening of genomic research, more and more non-coding RNAs have been identified, and their important role in gene expression regulation is becoming increasingly recognized. Circular RNA (circRNA) is a special type of non-coding RNA, a covalently closed ring formed during backsplicing. In eukaryotes, circRNA expression is extremely abundant and widespread in various organs and tissues, showing spatiotemporal and tissue specificity while also being evolutionarily conserved. CircRNA lacks a 5' cap structure and a 3' polyadenylated tail structure; instead, it is a closed loop, making it resistant to exonuclease degradation. Consequently, most circRNAs have a half-life exceeding 48 hours, compared to the average half-life of mRNA, which is only 10 hours.

[0007] Studies have shown that circular RNAs are widely involved in the development and progression of various diseases, providing theoretical support for elucidating disease mechanisms and offering new research ideas for the diagnosis and treatment of various diseases. The tissue-specific, disease-specific, and temporal-specific properties of circular RNAs, as well as their high stability, make them promising candidates for use as disease diagnostic markers.

[0008] Clinically, the diagnosis of stroke is mainly performed through computed tomography (CT) and magnetic resonance imaging (MRI), but both CT and MRI have some limitations in the diagnosis of stroke. First, CT examinations are not effective in judging early ischemic stroke. CT scans often cannot detect obvious abnormalities within 24 hours of the onset of cerebral infarction before the infarct is fully formed. At the same time, the radiation dose of CT is high, which can cause certain harm to the human body. Currently, there is no blood test indicator that can effectively diagnose stroke (for example, in addition to echocardiography, blood tests for myocardial infarction need to be supplemented with indicators such as cTNT). MRI can make up for the shortcomings of CT to a certain extent in the early diagnosis of stroke, but due to its working principle, MRI is not suitable for patients with pacemakers and magnetic metals in their bodies. MRI is also relatively expensive.

[0009] Therefore, finding a fast, accurate and inexpensive method for diagnosing stroke has become an important area to be addressed.

[0010] Summary of the Invention

[0011] Purpose of the Invention

[0012] The purpose of this application is to provide a circular RNA-circ-Magi1, a kit for diagnosing, assisting in the diagnosis or prognostic evaluation of stroke, a detection system for diagnosing, assisting in the diagnosis or prognostic evaluation of stroke, and the use of a detection reagent for circular RNA-circ-Magi1 in the preparation of a kit, test paper, chip or high-throughput sequencing platform for diagnosing, assisting in the diagnosis or prognostic evaluation of stroke.

[0013] Patients suspected of stroke can have their blood drawn directly for testing after admission to the hospital. By analyzing the expression level of circular RNA-circ-Magi1 in the blood or other tissues, stroke can be diagnosed or assisted in diagnosis, thereby improving the accuracy of early diagnosis of stroke.

[0014] Solution

[0015] To achieve the above objectives, according to the various embodiments of the present application, the present application provides the following technical solutions:

[0016] In a first aspect, the present application provides a kit for diagnosing, assisting in the diagnosis, or evaluating the prognosis of stroke, comprising a reagent and / or a test strip and / or a gene chip for detecting circular RNA-circ-Magi1. Optionally, the nucleotide sequence of the circular RNA-circ-Magi1 is as shown in SEQ ID NO: 1, and SEQ ID NO: 1 is specifically:

[0017] Furthermore, the detection reagent includes a detection primer and / or a probe, and the detection primer is a primer for amplifying the circular RNA-circ-Magi1; optionally, the detection primer includes the sequence shown in SEQ ID NO: 2 and SEQ ID NO: 3.

[0018] Furthermore, the detection primers are primers for amplifying the circular RNA-circ-Magi1, including the sequences shown in SEQ ID NO: 2 and SEQ ID NO: 3, specifically:

[0019] Furthermore, the detection primer is a fluorescent quantitative PCR primer set, which is used to detect the expression level of circular RNA-circ-Magi1; optionally, the detection reagent also includes a reagent used for real-time quantitative PCR.

[0020] Furthermore, RNA extraction reagents are also included.

[0021] Furthermore, cDNA reverse transcription reagents are also included.

[0022] Furthermore, the stroke is one or more of ischemic stroke, hemorrhagic stroke and lacunar stroke.

[0023] In a second aspect, a detection system for diagnosing, assisting in the diagnosis, or evaluating the prognosis of stroke is provided, comprising a detection system and an analysis system for quantitatively or relatively quantitatively detecting the expression level of circular RNA-circ-Magi1; the analysis system is used to diagnose or predict stroke based on the detected expression level of circular RNA-circ-Magi1; the analysis system stores a scoring model for predicting or evaluating stroke;

[0024] A possible scoring model is as follows: when the expression level of circular RNA-circ-Magi1 is higher than the set value P, it is positive for stroke; when it is lower than the set value P, it is negative for stroke.

[0025] Optionally, the circular RNA-circ-Magi1 is expressed at high levels in the blood of stroke patients.

[0026] Furthermore, the nucleotide sequence of the circular RNA-circ-Magi1 is shown in SEQ ID NO: 1.

[0027] Furthermore, the detection system comprises the kit according to any one of claims 3 to 5.

[0028] In a third aspect, a detection reagent for circular RNA-circ-Magi1 is provided for use in the preparation of a kit, test strip, chip, or high-throughput sequencing platform for diagnosing, assisting in the diagnosis, or evaluating the prognosis of stroke. Correspondingly, this can correspond to a method for diagnosing, assisting in the diagnosis, or evaluating the prognosis of stroke, wherein the content of circular RNA-circ-Magi1 in the blood is detected by a kit, test strip, chip, or high-throughput sequencing platform to diagnose or predict stroke.

[0029] Furthermore, the nucleotide sequence of the circular RNA-circ-Magi1 is shown in SEQ ID NO: 1.

[0030] Furthermore, the detection reagent includes detection primers for detecting the expression amount of circular RNA-circ-Magi1, and the detection primers include sequences shown in SEQ ID NO: 2 and SEQ ID NO: 3.

[0031] Furthermore, the stroke is one or more of ischemic stroke, hemorrhagic stroke and lacunar stroke.

[0032] Furthermore, the detection sample of the circular RNA-circ-Magi1 is blood.

[0033] Furthermore, the expression level is determined by detecting the amount of the RNA-circ-Magi1 in the blood. Optionally, the circular RNA-circ-Magi1 is expressed at a high level in the blood of stroke patients.

[0034] In a fourth aspect, a method for diagnosing, assisting in the diagnosis or evaluating the prognosis of stroke is provided, wherein the above kit is used to detect the expression level of circular RNA-circ-Magi1 in a test sample;

[0035] or

[0036] The above detection system is used to quantitatively or relatively quantitatively detect the expression level of circular RNA-circ-Magi1, and stroke is diagnosed or predicted based on the expression level of circular RNA-circ-Magi1.

[0037] Furthermore, the sample to be tested is whole blood, serum or plasma.

[0038] Furthermore, the stroke is one or more of ischemic stroke, hemorrhagic stroke and lacunar stroke.

[0039] Furthermore, the expression level is determined by detecting the amount of the RNA-circ-Magi1 in the blood. Optionally, the circular RNA-circ-Magi1 is expressed at a high level in the blood of stroke patients.

[0040] The details of one or more embodiments of the present application are set forth in the description below. Other features, objects, and advantages of the present application will become apparent from the description and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] In order to better describe and illustrate the embodiments and / or illustrations of the inventions disclosed herein, reference may be made to one or more of the accompanying drawings. The additional details or examples used to describe the accompanying drawings should not be considered to limit the scope of the disclosed inventions, the presently described embodiments and / or embodiments, and any of the best modes currently understood for these inventions.

[0042] Figure 1 shows the relative expression of circular RNA circ-Magi1 in various organs of mice in Example 1 of the present application;

[0043] Figure 2 shows the relative expression of circular RNA circ-Magi1 in various parts of mouse brain tissue in Example 1 of the present application;

[0044] FIG3 shows the expression of circular RNA circ-Magi1 in the HT22 cell line during oxygen-glucose deprivation, reoxygenation, and resugarization in Example 2 of the present application;

[0045] Figure 4 shows the relative expression of circular RNA circ-Magi1 in the H9c2 cell line during oxygen-glucose deprivation, reoxygenation, and resugarization in Example 2 of the present application;

[0046] FIG5 is a neurobehavioral score of MACO model mice in Example 3 of the present application;

[0047] FIG6 is the TTC staining result of the brain of MCAO model mice in Example 3 of the present application;

[0048] FIG7 is a statistical analysis of TTC staining results of MCAO model mouse brains in Example 3 of the present application;

[0049] FIG8 shows the expression of circular RNA circ-Magi1 in the brain of MCAO mice 24 hours after surgery in Example 4 of the present application;

[0050] Figure 9 shows the expression changes of circular RNA circ-Magi1 in the blood of MCAO mice 24 hours after surgery in Example 4 of the present application;

[0051] FIG10 is the relationship between the expression level of circular RNA circ-Magi1 in the blood and the area of ​​cerebral ischemia in MCAO mice 24 hours after surgery in Example 4 of the present application;

[0052] Figure 11 shows the expression of circ-Magi1 in the blood and blood cells of the control group and the MCAO model group in Example 4 of the present application;

[0053] FIG12 is an ROC curve of mouse stroke in Example 4 of the present application;

[0054] FIG13 shows the expression of circular RNA circ-Magi1 in the blood of stroke patients and healthy controls in Example 5 of the present application;

[0055] FIG14 is a graph showing the relationship between the infarct area and the relative expression level of circular RNA circ-Magi1 in human stroke in Example 5 of the present application;

[0056] FIG15 is the ROC curve of mouse stroke in Example 5 of the present application. DETAILED DESCRIPTION

[0057] In order to make the purpose, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be clearly and completely described below. Obviously, the described embodiments are part of the embodiments of the present application, rather than all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application. Unless otherwise expressly stated, throughout the specification and claims, the term "including" or its variations such as "comprising" or "including" will be understood to include the stated elements or components, without excluding other elements or other components.

[0058] In addition, in order to better illustrate the present application, numerous specific details are provided in the following detailed description. It should be understood by those skilled in the art that the present application can be implemented without certain specific details. In some embodiments, raw materials, components, methods, means, etc. well known to those skilled in the art are not described in detail in order to highlight the main purpose of the present application.

[0059] Hereinafter, this application will be described in detail.

[0060] The Magi1 protein belongs to the membrane-associated guanosine kinase family. It participates in the assembly of multimeric protein complexes and is localized at cell junctions, where it functions as a scaffold protein in establishing cell junctions, maintaining cell morphology, and signaling. During transcription, the Magi1 gene undergoes alternative splicing, generating multiple mRNAs that encode various Magi1 isoforms. circ-Magi1 is a circular RNA molecule formed by reverse splicing of exon 3 and exon 4 of the Magi1 gene. The molecular characteristics and biological functions of circ-Magi1 have not yet been reported.

[0061] This application uses qPCR detection methods to confirm that the expression of circular RNA circ-Magi1 (hereinafter referred to as circ-Magi1) in the mouse hippocampal neuronal cell line (HT22) is induced by hypoxia and glucose deprivation, and the expression of circ-Magi1 is further induced after the restoration of oxygen and glucose. That is, the expression of circ-Magi1 in nerve cells is significantly increased under hypoxia and glucose deprivation; while the expression of circular RNA circ-Magi1 in the rat cardiomyocyte cell line (H9c2) is not significantly changed under hypoxia, indicating that the expression of circ-Magi1 induced by hypoxia and glucose deprivation is neural specific. The increase in circ-Magi1 expression in the plasma of the MCAO model but not in the blood cells indicates that the change in the expression of circular RNA circ-Magi1 in the blood is caused by the release of circ-Magi1 into the blood due to nerve cell damage. The expression level of circ-Magi1 in the blood of the established mouse MCAO animal model and in the blood samples of stroke patients was positively correlated with the area of ​​cerebral ischemia, indicating that the expression level of circ-Magi1 was positively correlated with MCAO stroke, and circular RNA circ-Magi1 can be used as a stroke biomarker.

[0062] The inventors of this application also collected blood samples from ischemic stroke patients after they were diagnosed with stroke. Compared with blood samples from healthy people, the expression of circ-Magi1 in the blood of stroke patients was significantly increased, indicating that circular RNA circ-Magi1 can be used as a stroke biomarker, providing a fast, accurate and inexpensive method for the diagnosis or auxiliary diagnosis of stroke, which can improve the accuracy of early diagnosis of stroke to avoid missing the golden time for treatment.

[0063] This application also provides new ideas for the prevention and treatment of stroke.

[0064] The nucleotide sequences involved in this application are:

[0065] Human circ-Magi1 sequence (SEQ ID NO: 1):

[0066] Human circ-Magi1 qPCR primers:

[0067] Mouse circ-Magi1 sequence (SEQ ID NO: 4):

[0068] Mouse circ-Magi1 qPCR primers:

[0069] Among them, the human and mouse circ-Magi1 qPCR primers were obtained by artificial synthesis.

[0070] The cell lines cultured in this application are commercially available cell lines. For example, the mouse hippocampal neuronal cell line (HT22) and the rat myocardial cell line (H9c2) are both conventional commercial products, and cell lines derived from the ATCC cell bank can be used.

[0071] The biological materials used in this application, such as mice, are all commercially available. For example, C57BL male black mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0072] Example 1 circ-Magi1 is highly expressed in mouse brain tissue

[0073] Five 8-week-old C57BL male black mice were selected and killed by cervical dislocation. The heart, liver, spleen, lungs, kidneys, small intestine, stomach, brain, bladder, testicles, skeletal muscle, esophagus and other tissues and organs were collected for RNA extraction. The expression of circ-Magi1 was detected by qPCR (using mouse circ-Magi1 qPCR primers). The results are shown in Figure 1. The results show that circ-Magi1 is highly expressed in brain tissue (a mixture of various parts of brain tissue).

[0074] To further analyze the expression of circ-Magi1 in various brain regions, five 8-week-old C57BL male mice were again sacrificed by cervical dislocation. The following brain tissue structures were collected: cerebral cortex, hippocampus, brainstem, cerebellum, thalamus, hypothalamus, and olfactory bulb. RNA was extracted, and circ-Magi1 expression was detected by qPCR (using mouse circ-Magi1 qPCR primers). The results are shown in Figure 2. High expression was found in the hypothalamus and olfactory bulb, while low expression was found in the hippocampus.

[0075] Example 2 Expression of circ-Magi1 in mouse neurons during oxygen-glucose deprivation, reoxygenation, and resugarization

[0076] After the mouse hippocampal neuronal cell line (HT22) cells adhered to the wall, the low-glucose medium was replaced and the cells were cultured in a cell culture incubator with 1% O2, 5% CO2 and saturated humidity for 24 hours. Then, the medium was replaced with high-glucose medium and the cells were cultured in a cell culture incubator with 5% CO2 and saturated humidity for another 24 hours. The expression of circ-Magi1 was detected at 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, and 24 hours of oxygen and glucose deprivation and 3 hours, 6 hours, 12 hours, and 24 hours of reoxygenation. As shown in Figure 3, oxygen and glucose deprivation induced the expression of circ-Magi1, and the recirculation of oxygen and glucose further induced the expression of circ-Magi1 (n=3). That is, the expression level of circ-Magi1 RNA in nerve cells increased significantly under oxygen and glucose deprivation conditions. The expression level began to double at 12 hours and reached 5 times at 24 hours. That is, the expression level reached 2 to 5 times from 12 hours to 24 hours, and was further induced to increase after reoxygenation and resugaration.

[0077] We further studied the expression of circ-Magi1 in the rat cardiomyocyte cell line H9c2 under hypoxia and glucose deprivation conditions to verify the expression of circ-Magi1 in the cardiomyocyte cell line. The results are shown in Figure 4. There was no significant change in the expression of circ-Magi1 in the H9c2 cardiomyocyte cell line under hypoxia, indicating that hypoxia does not cause significant changes in the expression of circ-Magi1 in cardiomyocytes.

[0078] The results showed that oxygen-glucose deprivation induced circ-Magi1 expression with neural specificity, indicating that the changes in circ-Magi1 expression in the blood originated from nerve cells.

[0079] Example 3 Establishment of MCAO (middle cerebral artery occlusion) animal model in mice

[0080] Eight-week-old C57BL male mice (three in the control group and eight in the control group) underwent MCAO surgery: a 2-cm midline incision was made in the neck, and the right common carotid artery (CCA) was isolated and ligated. The external carotid artery (ECA) and internal carotid artery (ICA) were then isolated and ligated proximally and distally. The ICA was clamped with a vascular clip. A small incision was made between the two ligatures in the ECA, and a suture was inserted through the incision. The ECA was then cut and transposed, and the suture was inserted approximately 9 mm into the ICA. After 1 hour, the suture was removed, and the neck incision was sutured.

[0081] Behavioral scoring was performed on the MCAO mice 24 hours after the operation. The results are shown in FIG5 . The MACO animal model mice developed obvious behavioral disorders, indicating that the MCAO animal model was successfully established.

[0082] The extent of cerebral infarction in MCAO model mice was identified by TTC staining.

[0083] The TTC staining procedure is as follows: After the animal is sacrificed by decapitation, the brain is quickly removed (within 10 minutes), transferred to a PBS solution at 0-4°C, and frozen at -20°C for 30 minutes. The cerebellum, olfactory bulb, and lower brainstem are removed. Coronal brain slices are cut to a thickness of 2 mm and placed in a 2% red tetrazolium solution in a dark bath at 37°C for 30 minutes, gently shaking the container every 5 minutes to ensure thorough staining. The brain slices are removed and washed with PBS for 3-5 minutes. Immediately photograph the slices, which can be fixed with 10% neutral formaldehyde for 6 hours. The caudal aspect of each slice is photographed and analyzed, as shown in Figure 6. The infarct area and total area of ​​each slice are measured. The infarct volume of each slice is the product of the infarct area and slice thickness. The sum of the infarct volumes of each slice is the total infarct volume, as shown in Figure 7.

[0084] The results showed that the infarct volume of the MCAO model accounted for about 28% of the total area, which was significantly higher than that of the control group, indicating that the model was successful.

[0085] Example 4 Analysis of circ-Magi1 expression in the brain of MCAO animal model mice

[0086] The expression of circ-Magi1 in the brains of healthy mice and MCAO model mice 24 hours after surgery was analyzed by qPCR. The left and right brains of healthy mice, the left brain of MCAO mice, the injured area of ​​MCAO mice, and the injured boundary area of ​​MCAO mice were tested respectively. The results are shown in Figure 8. The results showed that the expression of circ-Magi1 was reduced in the stroke lesion area, while the expression was increased in the boundary area.

[0087] Circular RNA has a highly stable biological characteristic. By detecting the expression of RNA circ-Magi1 in the blood of healthy mice and MCAO animal model mice 24 hours after surgery, the results are shown in Figure 9. It was found that the expression of circ-Magi1 in the blood of MCAO animal model mice was significantly increased. By detecting the relationship between the infarct area of ​​mice and the expression of RNA circ-Magi1, the results are shown in Figure 10. The results show that the expression of RNA circ-Magi1 in the blood is positively correlated with the degree of brain stroke in MCAO mice. 2 =0.8824 (as shown in Figure 10).

[0088] We further analyzed the expression of circ-Magi1 in the plasma and blood cells of healthy mice and MCAO animal model mice 24 hours after surgery. The results are shown in Figure 11. It was found that the expression of circ-Magi1 in the blood cells of MCAO animal model mice remained unchanged compared with healthy mice, and the expression level of RNA circ-Magi1 in the blood of MCAO animal model mice was significantly higher than that of healthy mice, indicating that the change in circ-Magi1 expression in the blood originated from circ-Magi1 free from cells in the plasma.

[0089] The ROC curve (Receiver Operating Characteristic Curve) is primarily used to evaluate the effectiveness of a specific indicator in classifying / diagnosing two types of subjects (such as patients and healthy subjects) and to identify the optimal indicator cutoff value for optimal classification. The ROC curve uses the true positive rate (TPR) as the ordinate and the false positive rate (FPR) as the abscissa. 1) The true positive rate (TPR) is the ratio of the number of samples correctly classified as positive to the number of samples that are actually positive. TPR is also known as sensitivity. 2) The false positive rate (FPR) is the ratio of the number of samples incorrectly classified as positive to the number of samples that are actually negative. FPR is equal to 1-specificity. The true positive rate reflects the coverage of the indicator's predicted response, while the false positive rate reflects the degree of falsely reported response. Therefore, a higher true positive rate and a lower false negative rate indicate a better indicator response. This is reflected in the ROC graph as a steeper curve that protrudes to the upper left, indicating a better indicator response. The prediction effect of the indicator was evaluated by calculating the area under the curve (AUC) value, and the ideal AUC value = 1.

[0090] Twelve MCAO model mice and six control mice were included, and the ROC curve was drawn using SPSS. The ROC curve results for mice are shown in Figure 12. The results showed that the area under the curve (AUC) value was 0.944, P = 0.003 (as shown in the table below), indicating that the diagnostic accuracy is high and the degree of stroke can be diagnosed based on the expression of RNA circ-Magi1 in the blood.

[0091] Example 5 Analysis of circ-Magi1 expression in the blood of patients with ischemic stroke

[0092] Blood samples were collected from patients with ischemic stroke within 24 hours of being diagnosed with stroke (blood samples and CT tests were collected as soon as the patient was admitted to the hospital). For example, Wang *quan, male, 83 years old, was admitted to the EICU department of Puyang Oilfield General Hospital on March 20, 2021. He was diagnosed with ischemic stroke by CT examination and belonged to the ischemic stroke patient group; Wang *shan, male, 67 years old, was admitted to the emergency department of Puyang Oilfield General Hospital on April 17, 2021. He was diagnosed with ischemic stroke by CT examination and belonged to the ischemic stroke patient group; Li *yu, male, 49 years old, was admitted to the emergency department of Puyang Oilfield General Hospital on April 17, 2021. He was diagnosed with ischemic stroke by CT examination and belonged to the ischemic stroke patient group.

[0093] The control group was blood samples from healthy people who did not suffer from stroke.

[0094] The samples were collected from Puyang Oilfield General Hospital. With the approval of the Medical Ethics Committee of Puyang Oilfield General Hospital, all subjects who met the inclusion criteria in this study were informed and signed the informed consent.

[0095] The expression of circ-Magi1 in the blood of ischemic stroke patients was analyzed by qPCR. As shown in Figure 13, it was found that compared with normal controls, the expression of circ-Magi1 in the blood of ischemic stroke patients was significantly increased, which was about 25 times the expression level of circ-Magi1 in healthy controls.

[0096] By detecting the degree of MCAO human brain stroke and the expression of circ-Magi1 in the blood, as shown in Figure 14, the results showed that the expression of circ-Magi1 in the blood was positively correlated with the degree of MCAO human brain stroke, that is, the larger the infarct area, the higher the relative expression of circ-Magi1, and the R 2 =0.6358.

[0097] By collecting blood samples as soon as patients are admitted to the hospital, the results can usually be obtained within 1 hour, which can improve the accuracy of early diagnosis and avoid missing the golden time for treatment.

[0098] Forty-one patients with ischemic stroke and 10 normal controls were included, and the ROC curve was drawn using SPSS. The ROC curve of the patient's blood is shown in Figure 15. The results showed that the area under the curve (AUC) value was 0.866, P = 0.0003 (as shown in the table below), indicating that the diagnostic accuracy is high and the degree of stroke can be diagnosed based on the expression of RNA circ-Magi1 in the blood.

[0099] The above examples show that the expression level of circular RNA circ-Magi1 in stroke patients is significantly higher than that in healthy people, which can be used as an indicator for diagnosing stroke and also provides ideas for treating stroke by reducing the expression of circular RNA circ-Magi1.

[0100] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit them. Although the present application has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present application.

Claims

1. A kit for diagnosing, assisting in the diagnosis or evaluating the prognosis of stroke, It is characterized in that It includes reagents and / or test strips and / or gene chips for detecting circular RNA-circ-Magi1. Optionally, the nucleotide sequence of the circular RNA-circ-Magi1 is as shown in SEQ ID NO:

1.

2. The kit according to claim 1, It is characterized in that The detection reagent includes a detection primer and / or a probe and / or a chip, wherein the detection primer is a primer for amplifying the circular RNA-circ-Magi1; Optionally, the detection primers include the sequences shown in SEQ ID NO: 2 and SEQ ID NO: 3; Optionally, the detection primer is a fluorescent quantitative PCR primer set, which is used to detect the expression level of circular RNA-circ-Magi1; optionally, the detection reagent also includes a reagent used for real-time quantitative PCR.

3. The kit according to claim 1 or 2, It is characterized in that Also included are reagents for RNA extraction; And / or, also includes cDNA reverse transcription reagents.

4. The kit according to claim 2 or 3, It is characterized in that The cerebral stroke is one or more of ischemic cerebral stroke, hemorrhagic cerebral stroke and lacunar cerebral stroke.

5. A detection system for diagnosing, assisting in the diagnosis or evaluating the prognosis of stroke, It is characterized in that It includes a detection system and an analysis system for quantitatively or relatively quantitatively detecting the expression level of circular RNA-circ-Magi1; The analysis system is used to diagnose or predict stroke based on the detection expression of circular RNA-circ-Magi1; the analysis system stores a scoring model for predicting or evaluating stroke.

6. The detection system according to claim 5, It is characterized in that The nucleotide sequence of the circular RNA-circ-Magi1 is shown in SEQ ID NO:

1.

7. The detection system according to claim 5 or 6, It is characterized in that The detection system comprises the kit according to any one of claims 3 to 5.

8. The detection system according to any one of claims 5 to 7, It is characterized in that The circular RNA-circ-Magi1 is expressed at high levels in the blood of stroke patients; And / or, when the expression level of circular RNA-circ-Magi1 is higher than the set value P, it is positive for stroke; when it is lower than the set value P, it is negative for stroke.

9. Use of a detection reagent for circular RNA-circ-Magi1 in the preparation of a kit, test paper, chip or high-throughput sequencing platform for diagnosis, auxiliary diagnosis or prognosis evaluation of stroke.

10. The use according to claim 9, It is characterized in that The nucleotide sequence of the circular RNA-circ-Magi1 is shown in SEQ ID NO: 1; And / or, the detection reagent includes a detection primer for detecting the expression amount of circular RNA-circ-Magi1, and the detection primer includes the sequences shown in SEQ ID NO: 2 and SEQ ID NO: 3; And / or, the stroke is one or more of ischemic stroke, hemorrhagic stroke and lacunar stroke; And / or, the detection sample of the circular RNA-circ-Magi1 is whole blood or serum or plasma; And / or, the expression level is determined by detecting the amount of the RNA-circ-Magi1 in the blood. Optionally, the circular RNA-circ-Magi1 is expressed at a high level in the blood of stroke patients.

11. A method for diagnosing, assisting in the diagnosis or evaluating the prognosis of stroke, It is characterized in that Using the kit according to any one of claims 1 to 4 to detect the expression level of circular RNA-circ-Magi1 in the sample to be tested; or The detection system described in any one of items 5 to 8 is used to quantitatively or relatively quantitatively detect the expression level of circular RNA-circ-Magi1, and stroke is diagnosed or predicted based on the expression level of circular RNA-circ-Magi1.

12. The method according to claim 11, It is characterized in that The sample to be tested is whole blood, serum or plasma; And / or, the stroke is one or more of ischemic stroke, hemorrhagic stroke and lacunar stroke; And / or, the expression level is determined by detecting the amount of RNA-circ-Magi1 in the blood. Optionally, the circular RNA-circ-Magi1 is expressed at high levels in the blood of stroke patients.